Cargando…
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
(1) Background: The oncology field has drastically changed with the advent of precision medicine, led by the discovery of druggable genes or immune targets assessed through next-generation sequencing. Biomarker-based treatments are increasingly emerging, and currently, six tissue-agnostic therapies...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144220/ https://www.ncbi.nlm.nih.gov/pubmed/37111371 http://dx.doi.org/10.3390/ph16040614 |
_version_ | 1785034049979416576 |
---|---|
author | Tateo, Valentina Marchese, Paola Valeria Mollica, Veronica Massari, Francesco Kurzrock, Razelle Adashek, Jacob J. |
author_facet | Tateo, Valentina Marchese, Paola Valeria Mollica, Veronica Massari, Francesco Kurzrock, Razelle Adashek, Jacob J. |
author_sort | Tateo, Valentina |
collection | PubMed |
description | (1) Background: The oncology field has drastically changed with the advent of precision medicine, led by the discovery of druggable genes or immune targets assessed through next-generation sequencing. Biomarker-based treatments are increasingly emerging, and currently, six tissue-agnostic therapies are FDA-approved. (2) Methods: We performed a review of the literature and reported the trials that led to the approval of tissue-agnostic treatments and ongoing clinical trials currently investigating novel biomarker-based approaches. (3) Results: We discussed the approval of agnostic treatments: pembrolizumab and dostarlimab for MMRd/MSI-H, pembrolizumab for TMB-H, larotrectinib and entrectinib for NTRK-fusions, dabrafenib plus trametinib for BRAF V600E mutation, and selpercatinib for RET fusions. In addition, we reported novel clinical trials of biomarker-based approaches, including ALK, HER2, FGFR, and NRG1. (4) Conclusions: Precision medicine is constantly evolving, and with the improvement of diagnostic tools that allow a wider genomic definition of the tumor, tissue-agnostic targeted therapies are a promising treatment strategy tailored to the specific tumor genomic profile, leading to improved survival outcomes. |
format | Online Article Text |
id | pubmed-10144220 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101442202023-04-29 Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics Tateo, Valentina Marchese, Paola Valeria Mollica, Veronica Massari, Francesco Kurzrock, Razelle Adashek, Jacob J. Pharmaceuticals (Basel) Review (1) Background: The oncology field has drastically changed with the advent of precision medicine, led by the discovery of druggable genes or immune targets assessed through next-generation sequencing. Biomarker-based treatments are increasingly emerging, and currently, six tissue-agnostic therapies are FDA-approved. (2) Methods: We performed a review of the literature and reported the trials that led to the approval of tissue-agnostic treatments and ongoing clinical trials currently investigating novel biomarker-based approaches. (3) Results: We discussed the approval of agnostic treatments: pembrolizumab and dostarlimab for MMRd/MSI-H, pembrolizumab for TMB-H, larotrectinib and entrectinib for NTRK-fusions, dabrafenib plus trametinib for BRAF V600E mutation, and selpercatinib for RET fusions. In addition, we reported novel clinical trials of biomarker-based approaches, including ALK, HER2, FGFR, and NRG1. (4) Conclusions: Precision medicine is constantly evolving, and with the improvement of diagnostic tools that allow a wider genomic definition of the tumor, tissue-agnostic targeted therapies are a promising treatment strategy tailored to the specific tumor genomic profile, leading to improved survival outcomes. MDPI 2023-04-19 /pmc/articles/PMC10144220/ /pubmed/37111371 http://dx.doi.org/10.3390/ph16040614 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Tateo, Valentina Marchese, Paola Valeria Mollica, Veronica Massari, Francesco Kurzrock, Razelle Adashek, Jacob J. Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics |
title | Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics |
title_full | Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics |
title_fullStr | Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics |
title_full_unstemmed | Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics |
title_short | Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics |
title_sort | agnostic approvals in oncology: getting the right drug to the right patient with the right genomics |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144220/ https://www.ncbi.nlm.nih.gov/pubmed/37111371 http://dx.doi.org/10.3390/ph16040614 |
work_keys_str_mv | AT tateovalentina agnosticapprovalsinoncologygettingtherightdrugtotherightpatientwiththerightgenomics AT marchesepaolavaleria agnosticapprovalsinoncologygettingtherightdrugtotherightpatientwiththerightgenomics AT mollicaveronica agnosticapprovalsinoncologygettingtherightdrugtotherightpatientwiththerightgenomics AT massarifrancesco agnosticapprovalsinoncologygettingtherightdrugtotherightpatientwiththerightgenomics AT kurzrockrazelle agnosticapprovalsinoncologygettingtherightdrugtotherightpatientwiththerightgenomics AT adashekjacobj agnosticapprovalsinoncologygettingtherightdrugtotherightpatientwiththerightgenomics |